European and international collaboration in affinity proteomics

Area of Science:

• Proteomics
• Biotechnology
• Molecular Biology

Background:

• Affinity proteomics utilizes specific protein-binding molecules (binders), primarily antibodies, as reagents for proteome analysis.
• Advances in binder technologies offer new insights into protein expression, distribution, and function in various biological contexts.
• Key strengths include in situ detection, high sensitivity for low-abundance proteins, and functional interference in living cells.

Discussion:

• Comprehensive and standardized binder collections are essential to maximize the impact of affinity proteomics.
• The EU FP7 AFFINOMICS program, along with preceding initiatives, focuses on generating a large-scale resource of validated binders for human proteome characterization.
• This involves producing binders for approximately 1000 protein targets, particularly in signal transduction and cancer pathways, through a high-throughput production pipeline.

Key Insights:

• AFFINOMICS emphasizes efficient recombinant selection methods (phage, cell, ribosome display) for high-quality binder production at reduced cost and increased throughput.
• The program integrates innovative detection technologies for target proteins and their interactions.
• Binders are being deployed in proteomics studies with clinical relevance.

Outlook:

• International recognition of binder generation programs is growing, with parallel initiatives in the USA (NCI, NIH) and HUPO.
• The AFFINOMICS consortium organized the 5th ESF Workshop on Affinity Proteomics, highlighting collaborative efforts in the field.
• Future work will focus on expanding binder resources and their application in understanding complex biological systems and diseases.